science
Hosted by Creative Educational Concepts · science · EN-US
Welcome to CEConversations, a clinical podcast presented by Creative Educational Concepts designed to improve clinician performance and optimize patient outcomes.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
32%
Guest openness
Selective
Sign up to generate a grounded pitch for CEConversations.
Signup to Generate a PitchWelcome to CEConversations, a clinical podcast presented by Creative Educational Concepts designed to improve clinician performance and optimize patient outcomes.
CEConversations is hosted by Creative Educational Concepts. The show has published 48 episodes to date.
Recent episodes include "Webcast Finding the Right Rhythm: Supporting Pediatric Oncology Nurses in Longitudinal NF1 Management" (28 October 2026, 56 minutes), "Webcast: Rare, Complex, and Under-Recognized: Supporting Oncology Nurses in the Care of Patients with NF1" (6 August 2026, 52 minutes), and "A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC" (1 July 2026, 68 minutes).
CEConversations publishes roughly every few months, with episodes averaging 57 minutes across 48 episodes.
Booking probability for CEConversations is 32%, and the host is rated Selective on guests. CEConversations requires a Pod Score of 80 or higher. CEConversations's contact route on record: verified email.
The strongest fits for CEConversations are Health & Wellness Services and Courses, Coaching & Lessons. CEConversations has a science audience.
Creative Educational Concepts hosts CEConversations, a science podcast with 48 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
CEConversations
In this CE Concepts recorded symposium, faculty will apply NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs in pediatric patients. Learners will be shown how to incorporate MEK...
CEConversations
Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in...
CEConversations
Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a...
CEConversations
Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely...
CEConversations
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform...
CEConversations
Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of...
CEConversations
We explore how new non‑factor options and high‑sustained factor products are changing hemophilia care and why shared decision making leads to better, more flexible lives. We connect treatment choice to joint health...
CEConversations
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex...
CEConversations
| Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse...
CEConversations
| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of...
CEConversations
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of...
CEConversations
In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the...
CEConversations
In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline...
CEConversations
In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated...
CEConversations
In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for...
CEConversations
In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based...
CEConversations
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and...
CEConversations
The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical...
CEConversations
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of...
CEConversations
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on...
Recent guests on CEConversations. Study who booked and why before you pitch.
Vice President - Corporate Real Estate, Gennova Biopharmaceuticals
Director, Women’s Cancers Program; Division Chief, Breast Medical Oncology; Professor, Department of Medical Oncology and Therapeutic Research, University of California San Francisco Comprehensive Cancer Center
University of Kentucky College of Pharmacy
PitchCentric classifies CEConversations under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
